Sunday, May 12, 2019

Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in a small percentage of patients.


from Reuters: Health News https://reut.rs/2HbDAZA

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner